Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma

AI Briefing

• – Secura Bio's duvelisib shows promising results in treating relapsed/ refractory peripheral T-cell lymphoma
• – The Phase 2 trial demonstrated clinically meaningful response rates, including a substantial proportion of complete responses
• – Duvelisib was found to be effective in a heavily pretreated population